Skip to Contents

Skip to Contents

Meet Us at ADA 2026

Meet Us at ADA 2026.

HM17321, a CRFR2 Selective UCN2 Analog, Prevents Muscle Loss and Functional Decline in Sarcopenic Mice
Presentation Number
1783-P
Session
Sunday General Poster Session, Jun. 7 at 12:30-13:30 PM
Presenter
Dahae Lee, Ph.D /
Hanmi Pharmaceutical Co., Ltd.
Protective Effects of HM17321, a Novel UCN2 Analog, on Obesity-Associated Musculoskeletal Diseases in Mouse Models
Presentation Number
1803-P
Session
Sunday General Poster Session, Jun. 7 at 12:30-13:30 PM
Presenter
Hyunjoo Kwon, Ph.D /
Hanmi Pharmaceutical Co., Ltd.
Body Composition and Functional Outcomes of HM17321, a CRFR2-Selective UCN2 Analog, Alone and in Combination with Myostatin/Activin Inhibition in DIO Mice
Presentation Number
2537-P
Session
ePoster Theater - Obesity Treatment: Comparisons, Outcomes, and Effects, Jun. 7 at 12:10~12:20 PM / Monday General Poster Session, Jun. 8 at 12:30-13:30 PM
Presenter
Seon Myeong Lee /
Hanmi Pharmaceutical Co., Ltd.
Cardiorenal protective effects of a CRFR2-selective UCN2 analog, HM17321, in spontaneously hypertensive rats (SHR)
Presentation Number
2538-P
Session
Monday General Poster Session, Jun. 8 at 12:30-13:30 PM
Presenter
Seon Myeong Lee /
Hanmi Pharmaceutical Co., Ltd.
Temporal Mechanistic Shifts Underlying Sustained Muscle Growth by HM17321 Revealed by Tissue Proteome Analysis
Presentation Number
2579-P
Session
Monday General Poster Session, Jun. 8 at 12:30-13:30 PM
Presenter
Boram Kim, Ph.D /
Hanmi Pharmaceutical Co., Ltd.
Cardioprotective Effects of HM17321, a Novel UCN2 Analog, in Rodent Heart Failure Models and a Translational Nonhuman Primate Model
Presentation Number
2872-LB
Session
Late Breaking Poster Session, Jun. 7 at 12:30-13:30 PM
Presenter
Byeongjin Ye, Ph.D /
Hanmi Pharmaceutical Co., Ltd.
HM500197, a De Novo-Designed Long-Acting Peptide Myostatin Inhibitor, Improves Skeletal Muscle Mass and Body Composition in Diet-Induced Obese Mice
Presentation Number
3073-LB
Session
Late Breaking Poster Session, Jun. 7 at 12:30-13:30 PM
Presenter
Jaehyuk Choi, Ph.D /
Hanmi Pharmaceutical Co., Ltd.
HM17321, a Novel UCN2 Analog, Improves Weight Loss Quality in Combination with Amylin Analogs in DIO Rats
Presentation Number
3078-LB
Session
Late Breaking Poster Session, Jun. 7 at 12:30-13:30 PM
Presenter
Yohan Kim /
Hanmi Pharmaceutical Co., Ltd.

Hanmi's New Story

Creativity, Innovation, and Challenge
A New Era Takes Off at Hanmi

Focus on Making
Innovative Medicines

Hanmi Pharmaceutical is leading innovation in the
pharmaceutical industry with a sustainable R&D
infrastructure covering various therapeutic areas.

Obesity/Metabolism

Developing best-in-class drugs for obesity,
non-alcoholic steatohepatitis,
and more with multiple mechanisms of action

View More

ESG Report

Hanmi ESG is Everyday-life Innovation

View More

Your dream is our future.
Hanmi awaits you.

Join Us